Reinsurance Group price target raised to $239 from $236 at Wells Fargo

Wells Fargo raised the firm’s price target on Reinsurance Group to $239 from $236 and keeps an Overweight rating on the shares after hosting a call with executives highlighting the opportunity the company has with GLP-1 drugs. Management likened the GLP-1 rollout to the introduction of statins and Protease inhibitors and that while pricing does not yet include the potential positive impacts from GLP-1s, management does expect a positive adjustment to be made down the road, as the drug should have a net positive impact on its overall business, the analyst tells investors in a research note.